Genetic Causes of Cerebrovascular Disorders in Childhood

Total Page:16

File Type:pdf, Size:1020Kb

Genetic Causes of Cerebrovascular Disorders in Childhood Genetic Causes of Cerebrovascular Disorders in Childhood Marije Meuwissen Genetic Causes of Cerebrovascular Disorders in Childhood Cover photo: Robert Ludlow, UCL Institute of Neurology, Wellcome Images (used with permission) Cover design and layout: R. Grefhorst Printing: Druk. Tan Heck, Delft © 2014, M.E.C. Meuwissen All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, mechanical, photocopy, recording or otherwise, without the written permission of the author. ISBN: 978-90-6824-047-4 The work presented in this thesis was performed at the Department of Clinical Genetics at the Erasmus University Medical Center, Rot- terdam This work was financially supported by Fonds NutsOhra Genetic Causes of Cerebrovascular Disorders in Childhood Genetische oorzaken van cerebrovasculaire aandoeningen op de kinderleeftijd Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. H.A.P. Pols en volgens besluit van het College voor Promoties De openbare verdediging zal plaatsvinden op Woensdag 2 april om 15:30 uur door Marije Ellen Carolien Meuwissen geboren te Leidschendam PROMOTIECOMMISSIE Promotor Prof. dr. R.M.W. Hofstra Co-promotor Dr. G.M.S. Mancini Overige leden Prof. dr. I.K.M. Reiss Prof. dr. R.C.M. Hennekam Prof. dr. K. Braun Het verschijnen van dit proefschrift werd mede mogelijk gemaakt door de steun van de Nederlandse Hartstichting. CONTENTS GENERAL INTRODUCTION Chapter 1 General introduction and outline of the thesis 11 PART I GENETIC CAUSES OF ISCHEMIC STROKE Chapter 2.1 ACTA2 mutation with childhood cardiovascular, autonomic 45 and brain anomalies and severe outcome Chapter 2.2 Neurological findings in Incontinentia Pigmenti; a review 57 PART II GENETIC CAUSES OF HEMORRHAGIC STROKE Chapter 3 The expanding phenotype of COL4A1 and COL4A2 mutations; 81 clinical data on 13 newly identified families and review of literature Chapter 4.1 Sporadic COL4A1 mutations with extensive prenatal 107 porencephaly resembling hydranencephaly Chapter 4.2 Novel COL4A1 mutation in familial anterior segment dysgenesis 117 Chapter 4.3 Is autosomal recessive inheritance possible in hereditary 125 porencephaly due to COL4A1 mutations? Chapter 5 COL4A2 mutation associated with familial porencephaly 133 and small-vessel disease Chapter 6 Interferon type 1 response regulator USP18 is 163 mutated in severe pseudo-TORCH syndrome DISCUSSION AND SUMMARY Chapter 7 General discussion 193 Summary 213 Samenvatting 219 Curriculum Vitae 225 PhD Portfolio 227 List of publications 231 Dankwoord 235 Colour figures 241 INTRODUCTION Chapter 1 GENERAL INTRODUCTION AND OUTLINE OF THE THESIS GENERAL INTRODUCTION Cerebrovascular disorders are defined as focal cerebral injury with an underlying vascular basis and can be divided in stroke resulting from arterial ischemic event, cerebral sinove- nous thrombosis and hemorrhage1. Stroke at young age (< age 18) is not common, but is an important cause of lifelong morbidity and is among the top ten causes of death in child- hood2-4. It has an incidence of approximately 1.3-13 per 100.000 per year in the developed countries. Causes, risk factors and pathogenic mechanisms of pediatric stroke differ in the perinatal period or in childhood. Pediatric arterial ischemic stroke Arterial ischemic stroke (AIS) in childhood is usually non-atherosclerotic, which is differ- ent from the adult population. In half of the children with AIS, a pre-existing condition can be identified, such as congenital heart disease or sickle cell disease; in the other part it remains uncertain and may be due to an interplay of both genetic and environmental factors. AIS can occur for example in the presence of genetic prothrombotic disorders, but also in the context of a metabolic disease (Fabry disease, congenital disorders of glycosylation) or other underlying genetic cerebral arteriopathies. In the perinatal period, most relevant risk factors are linked to maternal risk factors, such as autoimmune disease, preeclamp- sia, traumas, and neonatal, such as infection, systemic illness (including inborn errors of metabolism) and complex congenital heart disease. Very few genetic causes are known. In the first part of this thesis, two examples of genetic disorders leading to ischemic cerebral arteriopathy, Incontinentia pigmenti and ACTA2 mutations, are described in more detail. Pediatric Hemorrhagic stroke In the main part of this thesis, we will focus on processes underlying cerebral hemorrhage occurring at young age, mostly in the perinatal and infantile period. In the childhood pop- ulation, the proportion of hemorrhagic stroke is approximately 50%, versus only 15% in the adult population1,2,4. Hemorrhagic stroke (bleeding) is the result of a weakened vessel that ruptures and bleeds into the surrounding brain. Overall mortality of hemorrhagic stroke in children is approximately 25% and of those who survive, 42% shows signifi- cant disability5. Hemorrhagic stroke comprises spontaneous intracerebral (parenchymal and intraventricular) hemorrhage (ICH) and non-traumatic subarachnoid hemorrhage (SAH)2. A parenchymal hemorrhage is located within the brain parenchyma, whereas an General introduction and outline of the thesis 13 intraventricular hemorrhage is located inside the brain’s ventricular system. Subarachnoi- dal hemorrhages are located in the subarachnoidal space, the area between the arachnoid membrane and the pia mater, that surrounds the brain and are most often due to intracra- nial aneurysms6. Common risk factors for hemorrhagic stroke at young age are listed in Table 17. Most of them undely occurrence in childhood. Besides common risk factors, rare genetic causes of cerebral hemorrhage have been identified at any age, from pregnancy to adulthood and are summarized in Table 2, together with the known genetic causes of arte- rial ischemic stroke and our newly identified genes, which will be discussed in detail in this thesis. Neonatal/ infantile cerebral hemorrhage is a subset of the childhood intracerebral (paren- chymal or intraventricular) hemorrhage and among all types pediatric strokes is the least well characterized. It is often regarded as non-genetic, and risk factors include low birth weight and prematurity8-11. It usually presents as a germinal matrix hemorrhage or intraven- tricular hemorrhage. The germinal matrix a highly vascularized, transient layer near the ventricles that is present between 8 and 36 weeks of gestation. It has a role in the production of neurons and glial cells. The structure of the germinal matrix is selectively vulnerable to hemorrhage, which can be explained by limited astrocyte end-feet coverage of microvessels, reduced expression of fibronectin, an extracellular matrix component, and immature tight junctions12. In approximately 15% of infants these hemorrhages lead to venous infarction Table 1. Risk factors for pediatric hemorrhagic stroke Arteriovenous malformations 14-50% Cerebral aneurysms 10-13% Cavernous malformations 15-25% Hematological abnormalities 10-30% Thrombocytopenia Idiopathic thrombocytopenia purpura (ITP) Hemophilia Coagulopathies Liver failure Disseminated intravascular coagulation Iatrogenic Sickle cell anemia Brain tumors 13% 14 Chapter 1 due to occlusion of the periventricular collector veins, subsequent tissue destruction and the development of porencephaly, defined as a cavity in the brain parenchyma commu- nicating with the lateral ventricle13. This process is depicted in Figure 1. The hemorrhage usually occurs at late pregnancy or around birth14. In case of early extensive hemorrhage, the destruction can extend to the cortex and can lead to major destructive lesions such as hydranencephaly15. Affected neonates have a high chance of developing long term com- plications, such as hydrocephaly, motor impairment such as cerebral palsy, intellectual disability or epilepsy, depending on the extension of the lesions. Already since the 1980s, familial occurrence of cerebral hemorrhage has been documented, for instance familial cases of porencephaly16-21. The discovery of an underlying genetic cause of childhood cerebral hemorrhage is of importance for appropriate genetic counselling. Expanding the knowledge on underlying mechanisms will hopefully result in the develop- ment of specific treatment and preventive options in the future. To achieve this, it is crucial to elucidate the pathogenic mechanisms underlying these disorders. By investigating the childhood population, we expect to find a greater influence of genetic factors compared to Figure 1. Schematic overview of pathogenic mechanism leading to porencephaly119,120. The lateral ventricles with surrounding deep veins are depicted in A. Porencephaly originates from a germinal matrix hemorrhage, often followed by intraventricular hemorrhage. This leads to deep venous infarctions and destruction of white matter in that area, eventually leading to a cyst communicating with the ventricle (B) General introduction and outline of the thesis 15 the adult population, since the role of additional environmental factors contributing to the hemorrhage is smaller. However, a common genetic factor may underly both neonatal and adult onset cerebral hemorrhage, due to variable expression, which is, for example, docu- mented for COL4A1 and COL4A2 mutations. Pathophysiological processes underlying the disorders described in this thesis The identification of genetic causes of cerebrovascular disease has led to the identification of
Recommended publications
  • The Counsyl Foresight™ Carrier Screen
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]
  • Disease Reference Book
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]
  • Alport Syndrome of the European Dialysis Population Suffers from AS [26], and Simi- Lar Figures Have Been Found in Other Series
    DOCTOR OF MEDICAL SCIENCE Patients with AS constitute 2.3% (11/476) of the renal transplant population at the Mayo Clinic [24], and 1.3% of 1,000 consecutive kidney transplant patients from Sweden [25]. Approximately 0.56% Alport syndrome of the European dialysis population suffers from AS [26], and simi- lar figures have been found in other series. AS accounts for 18% of Molecular genetic aspects the patients undergoing dialysis or having received a kidney graft in 2003 in French Polynesia [27]. A common founder mutation was in Jens Michael Hertz this area. In Denmark, the percentage of patients with AS among all patients starting treatment for ESRD ranges from 0 to 1.21% (mean: 0.42%) in a twelve year period from 1990 to 2001 (Danish National This review has been accepted as a thesis together with nine previously pub- Registry. Report on Dialysis and Transplantation in Denmark 2001). lished papers by the University of Aarhus, February 5, 2009, and defended on This is probably an underestimate due to the difficulties of establish- May 15, 2009. ing the diagnosis. Department of Clinical Genetics, Aarhus University Hospital, and Faculty of Health Sciences, Aarhus University, Denmark. 1.3 CLINICAL FEATURES OF X-LINKED AS Correspondence: Klinisk Genetisk Afdeling, Århus Sygehus, Århus Univer- 1.3.1 Renal features sitetshospital, Nørrebrogade 44, 8000 Århus C, Denmark. AS in its classic form is a hereditary nephropathy associated with E-mail: [email protected] sensorineural hearing loss and ocular manifestations. The charac- Official opponents: Lisbeth Tranebjærg, Allan Meldgaard Lund, and Torben teristic renal features in AS are persistent microscopic hematuria ap- F.
    [Show full text]
  • Its Place Among Other Genetic Causes of Renal Disease
    J Am Soc Nephrol 13: S126–S129, 2002 Anderson-Fabry Disease: Its Place among Other Genetic Causes of Renal Disease JEAN-PIERRE GRU¨ NFELD,* DOMINIQUE CHAUVEAU,* and MICHELINE LE´ VY† *Service of Nephrology, Hoˆpital Necker, Paris, France; †INSERM U 535, Baˆtiment Gregory Pincus, Kremlin- Biceˆtre, France. In the last two decades, decisive advances have been made in Nephropathic cystinosis, first described in 1903, is an auto- the field of human genetics, including renal genetics. The somal recessive disorder characterized by the intra-lysosomal responsible genes have been mapped and then identified in accumulation of cystine. It is caused by a defect in the transport most monogenic renal disorders by using positional cloning of cystine out of the lysosome, a process mediated by a carrier and/or candidate gene approaches. These approaches have that remained unidentified for several decades. However, an been extremely efficient since the number of identified genetic important management step was devised in 1976, before the diseases has increased exponentially over the last 5 years. The biochemical defect was characterized in 1982. Indeed cysteam- data derived from the Human Genome Project will enable a ine, an aminothiol, reacts with cystine to form cysteine-cys- more rapid identification of the genes involved in the remain- teamine mixed disulfide that can readily exit the cystinotic ing “orphan” inherited renal diseases, provided their pheno- lysosome. This drug, if used early and in high doses, retards the types are well characterized. We have entered the post-gene progression of cystinosis in affected subjects by reducing intra- era. What is/are the function(s) of these genes? What are the lysosomal cystine concentrations.
    [Show full text]
  • Genetic Disorder
    Genetic disorder Single gene disorder Prevalence of some single gene disorders[citation needed] A single gene disorder is the result of a single mutated gene. Disorder Prevalence (approximate) There are estimated to be over 4000 human diseases caused Autosomal dominant by single gene defects. Single gene disorders can be passed Familial hypercholesterolemia 1 in 500 on to subsequent generations in several ways. Genomic Polycystic kidney disease 1 in 1250 imprinting and uniparental disomy, however, may affect Hereditary spherocytosis 1 in 5,000 inheritance patterns. The divisions between recessive [2] Marfan syndrome 1 in 4,000 and dominant types are not "hard and fast" although the [3] Huntington disease 1 in 15,000 divisions between autosomal and X-linked types are (since Autosomal recessive the latter types are distinguished purely based on 1 in 625 the chromosomal location of Sickle cell anemia the gene). For example, (African Americans) achondroplasia is typically 1 in 2,000 considered a dominant Cystic fibrosis disorder, but children with two (Caucasians) genes for achondroplasia have a severe skeletal disorder that 1 in 3,000 Tay-Sachs disease achondroplasics could be (American Jews) viewed as carriers of. Sickle- cell anemia is also considered a Phenylketonuria 1 in 12,000 recessive condition, but heterozygous carriers have Mucopolysaccharidoses 1 in 25,000 increased immunity to malaria in early childhood, which could Glycogen storage diseases 1 in 50,000 be described as a related [citation needed] dominant condition. Galactosemia
    [Show full text]
  • Soonerstart Automatic Qualifying Syndromes and Conditions
    SoonerStart Automatic Qualifying Syndromes and Conditions - Appendix O Abetalipoproteinemia Acanthocytosis (see Abetalipoproteinemia) Accutane, Fetal Effects of (see Fetal Retinoid Syndrome) Acidemia, 2-Oxoglutaric Acidemia, Glutaric I Acidemia, Isovaleric Acidemia, Methylmalonic Acidemia, Propionic Aciduria, 3-Methylglutaconic Type II Aciduria, Argininosuccinic Acoustic-Cervico-Oculo Syndrome (see Cervico-Oculo-Acoustic Syndrome) Acrocephalopolysyndactyly Type II Acrocephalosyndactyly Type I Acrodysostosis Acrofacial Dysostosis, Nager Type Adams-Oliver Syndrome (see Limb and Scalp Defects, Adams-Oliver Type) Adrenoleukodystrophy, Neonatal (see Cerebro-Hepato-Renal Syndrome) Aglossia Congenita (see Hypoglossia-Hypodactylia) Aicardi Syndrome AIDS Infection (see Fetal Acquired Immune Deficiency Syndrome) Alaninuria (see Pyruvate Dehydrogenase Deficiency) Albers-Schonberg Disease (see Osteopetrosis, Malignant Recessive) Albinism, Ocular (includes Autosomal Recessive Type) Albinism, Oculocutaneous, Brown Type (Type IV) Albinism, Oculocutaneous, Tyrosinase Negative (Type IA) Albinism, Oculocutaneous, Tyrosinase Positive (Type II) Albinism, Oculocutaneous, Yellow Mutant (Type IB) Albinism-Black Locks-Deafness Albright Hereditary Osteodystrophy (see Parathyroid Hormone Resistance) Alexander Disease Alopecia - Mental Retardation Alpers Disease Alpha 1,4 - Glucosidase Deficiency (see Glycogenosis, Type IIA) Alpha-L-Fucosidase Deficiency (see Fucosidosis) Alport Syndrome (see Nephritis-Deafness, Hereditary Type) Amaurosis (see Blindness) Amaurosis
    [Show full text]
  • X Inactivation, Female Mosaicism, and Sex Differences in Renal Diseases
    BRIEF REVIEW www.jasn.org X Inactivation, Female Mosaicism, and Sex Differences in Renal Diseases Barbara R. Migeon McKusick-Nathans Institute of Genetic Medicine, Department of Pediatrics, Johns Hopkins University, Baltimore Maryland ABSTRACT A good deal of sex differences in kidney disease is attributable to sex differences expressed only in the testes, they have to do in the function of genes on the X chromosome. Males are uniquely vulnerable to with testicular function and fertility. With mutations in their single copy of X-linked genes, whereas females are often mosaic, one X chromosome, males have only a sin- having a mixture of cells expressing different sets of X-linked genes. This cellular gle copy of their X-linked genes. mosaicism created by X inactivation in females is most often advantageous, pro- On the other hand, even though fe- tecting carriers of X-linked mutations from the severe clinical manifestations seen males have two copies of these genes, in males. Even subtle differences in expression of many of the 1100 X-linked genes both are not expressed in the same cell. may contribute to sex differences in the clinical expression of renal diseases. Only one X is programmed to work in each diploid somatic cell. All of the other J Am Soc Nephrol 19: 2052–2059, 2008. doi: 10.1681/ASN.2008020198 X chromosomes in the cell become inac- tive during fetal development. Briefly, compensation for X dosage in our spe- Although being female conveys a protec- with normal kidney function. This re- cies is accomplished by a process that en- tive effect on the progression of chronic view addresses the genetic and epigenetic sures only a single X is active in both renal disease, the basis for this sex differ- programs that contribute to the sex dif- sexes.
    [Show full text]
  • Essential Genetics 5
    Essential genetics 5 Disease map on chromosomes 例 Gaucher disease 単一遺伝子病 天使病院 Prader-Willi syndrome 隣接遺伝子症候群,欠失が主因となる疾患 臨床遺伝診療室 外木秀文 Trisomy 13 複数の遺伝子の重複によって起こる疾患 挿画 Koromo 遺伝子の座位あるいは欠失等の範囲を示す Copyright (c) 2010 Social Medical Corporation BOKOI All Rights Reserved. Disease map on chromosome 1 Gaucher disease Chromosome 1q21.1 1p36 deletion syndrome deletion syndrome Adrenoleukodystrophy, neonatal Cardiomyopathy, dilated, 1A Zellweger syndrome Charcot-Marie-Tooth disease Emery-Dreifuss muscular Hypercholesterolemia, familial dystrophy Hutchinson-Gilford progeria Ehlers-Danlos syndrome, type VI Muscular dystrophy, limb-girdle type Congenital disorder of Insensitivity to pain, congenital, glycosylation, type Ic with anhidrosis Diamond-Blackfan anemia 6 Charcot-Marie-Tooth disease Dejerine-Sottas syndrome Marshall syndrome Stickler syndrome, type II Chronic granulomatous disease due to deficiency of NCF-2 Alagille syndrome 2 Copyright (c) 2010 Social Medical Corporation BOKOI All Rights Reserved. Disease map on chromosome 2 Epiphyseal dysplasia, multiple Spondyloepimetaphyseal dysplasia Brachydactyly, type D-E, Noonan syndrome Brachydactyly-syndactyly syndrome Peters anomaly Synpolydactyly, type II and V Parkinson disease, familial Leigh syndrome Seizures, benign familial Multiple pterygium syndrome neonatal-infantile Escobar syndrome Ehlers-Danlos syndrome, Brachydactyly, type A1 type I, III, IV Waardenburg syndrome Rhizomelic chondrodysplasia punctata, type 3 Alport syndrome, autosomal recessive Split-hand/foot malformation Crigler-Najjar
    [Show full text]
  • Genetic Testing Services and Support, from Preconception to Prenatal the Way Many Think About Carrier Screening Is Changing
    Genetic testing services and support, from preconception to prenatal The way many think about carrier screening is changing. Carrier screening, once thought to be a test primarily for specific ethnic groups, is now often recommended for every patient. The American Congress of Obstetricians and Gynecologists (ACOG) recently updated its recommendations, stating that carrier screening for spinal muscular atrophy (SMA), in addition to cystic fibrosis (CF), "should be offered to all women who are considering pregnancy or are currently pregnant."7 COMPREHENSIVE, VERSATILE, COVERING WHAT MATTERS Inheritest® provides carrier screening for more than 110 severe disorders that can cause cognitive or physical impairment and/or require surgical or medical intervention. Selected to focus on severe disorders of childhood onset, and to meet ACOG and the American College of Medical Genetics and Genomics (ACMG) criteria, many of the disorders share a recommendation for early intervention. Inheritest offers multiple panels to suit the diverse needs of your patients: Focuses on mutations for CF, SMA, and fragile X syndrome, with the following carrier risks: CORE PANEL CF: as high as 1 in 248 SMA: as high as 1 in 479 Fragile X syndrome: approximately 3 GENES (varies by ethnicity) (varies by ethnicity) 1 in 259 females (all ethnicities)10 SOCIETY-GUIDED PANEL Includes mutations for more than 13 disorders listed in ACOG and/or ACMG recommendations 14 GENES ASHKENAZI JEWISH Enhanced panel includes mutations for more than 40 disorders relevant to patients of Ashkenazi PANEL 48 GENES Jewish descent COMPREHENSIVE Includes mutations for more than 110 disorders across 144 different genes—includes all disorders in PANEL 144 GENES Core, Society-guided, and Ashkenazi Jewish panels THE CASE FOR EXPANDED CARRIER SCREENING While some providers may only screen for CF or select screening based on ethnicity, the case for more comprehensive screening is becoming clear.
    [Show full text]
  • Inheritest 500 PLUS
    Inheritest® 500 PLUS 525 genes Specimen ID: 00000000010 Container ID: H0651 Control ID: Acct #: LCA-BN Phone: SAMPLE REPORT, F-630049 Patient Details Specimen Details Physician Details DOB: 01/01/1991 Date Collected: 08/05/2019 12:00 (Local) Ordering: Age (yyy/mm/dd): 028/07/04 Date Received: 08/06/2019 Referring: Gender: Female Date Entered: 08/06/2019 ID: Patient ID: 00000000010 Date Reported: 08/21/2019 15:29 (Local) NPI: Ethnicity: Unknown Specimen Type: Blood Lab ID: MNEGA Indication: Carrier screening Genetic Counselor: None SUMMARY: POSITIVE POSITIVE RESULTS DISORDER (GENE) RESULTS INTERPRETATION Spinal muscular atrophy AT RISK AT RISK to be a silent carrier (2+0). For ethnic-specific risk (SMN1) 2 copies of SMN1; positive for revisions see Methods/Limitations. Genetic counseling is NMID: NM_000344 c.*3+80T>G SNP recommended. Risk: AT INCREASED RISK FOR AFFECTED PREGNANCY. See Additional Clinical Information. NEGATIVE RESULTS DISORDER (GENE) RESULTS INTERPRETATION Cystic fibrosis NEGATIVE This result reduces, but does not eliminate the risk to be a (CFTR) carrier. NMID: NM_000492 Risk: NOT at an increased risk for an affected pregnancy. Fragile X syndrome NEGATIVE: Not a carrier of a fragile X expansion. (FMR1) 29 and 36 repeats NMID: NM_002024 Risk: NOT at an increased risk for an affected pregnancy. ALL OTHER DISORDERS NEGATIVE This result reduces, but does not eliminate the risk to be a carrier. Risk: The individual is NOT at an increased risk for having a pregnancy that is affected with one of the disorders covered by this test. For partner's gene-specific risks, visit www.integratedgenetics.com.
    [Show full text]
  • A Model of Autosomal Recessive Alport Syndrome in English Cocker Spaniel Dogs
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 54 (1998), pp. 706–719 A model of autosomal recessive Alport syndrome in English cocker spaniel dogs GEORGE E. LEES,R.GAYMAN HELMAN,CLIFFORD E. KASHTAN,ALFRED F. MICHAEL,LINDA D. HOMCO, NICHOLAS J. MILLICHAMP,YOSHIFUMI NINOMIYA,YOSHIKAZU SADO,ICHIRO NAITO, and YOUNGKI KIM Texas Veterinary Medical Center, Texas A&M University, College Station, Texas, Oklahoma Animal Disease Diagnostic Laboratory, Oklahoma State University, Stillwater, Oklahoma, and Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA; Department of Molecular Biology and Biochemistry, Okayama University Medical School, Okayama, and Divisions of Immunology and Ultrastructural Biology, Shigei Medical Research Institute, Okayama, Japan A model of autosomal recessive Alport syndrome in English cause progressive glomerular disease [1–3]. In humans with cocker spaniel dogs. Alport syndrome (AS), the nephropathy is frequently asso- Background. Dogs with naturally occurring genetic disorders of basement membrane (type IV) collagen may serve as animal ciated with sensorineural hearing loss and ocular abnormal- models of Alport syndrome. ities. Distinctive ultrastructural changes in glomerular base- Methods. An autosomal recessive form of progressive heredi- ment membranes (GBM) of affected individuals is a tary nephritis (HN) was studied in 10 affected, 3 obligate carrier, prominent characteristic of these disorders [1–3]. and 4 unaffected English cocker spaniel (ECS) dogs. Clinical, In humans AS usually is X-linked, resulting from muta- pathological, and ultrastructural features of the disease were a characterized. Expression of basement membrane (BM) proteins tions in the COL4A5 gene, which encodes the 5 chain of was examined with an immunohistochemical technique using type IV collagen [1, 4].
    [Show full text]
  • EUROCAT Syndrome Guide
    JRC - Central Registry european surveillance of congenital anomalies EUROCAT Syndrome Guide Definition and Coding of Syndromes Version July 2017 Revised in 2016 by Ingeborg Barisic, approved by the Coding & Classification Committee in 2017: Ester Garne, Diana Wellesley, David Tucker, Jorieke Bergman and Ingeborg Barisic Revised 2008 by Ingeborg Barisic, Helen Dolk and Ester Garne and discussed and approved by the Coding & Classification Committee 2008: Elisa Calzolari, Diana Wellesley, David Tucker, Ingeborg Barisic, Ester Garne The list of syndromes contained in the previous EUROCAT “Guide to the Coding of Eponyms and Syndromes” (Josephine Weatherall, 1979) was revised by Ingeborg Barisic, Helen Dolk, Ester Garne, Claude Stoll and Diana Wellesley at a meeting in London in November 2003. Approved by the members EUROCAT Coding & Classification Committee 2004: Ingeborg Barisic, Elisa Calzolari, Ester Garne, Annukka Ritvanen, Claude Stoll, Diana Wellesley 1 TABLE OF CONTENTS Introduction and Definitions 6 Coding Notes and Explanation of Guide 10 List of conditions to be coded in the syndrome field 13 List of conditions which should not be coded as syndromes 14 Syndromes – monogenic or unknown etiology Aarskog syndrome 18 Acrocephalopolysyndactyly (all types) 19 Alagille syndrome 20 Alport syndrome 21 Angelman syndrome 22 Aniridia-Wilms tumor syndrome, WAGR 23 Apert syndrome 24 Bardet-Biedl syndrome 25 Beckwith-Wiedemann syndrome (EMG syndrome) 26 Blepharophimosis-ptosis syndrome 28 Branchiootorenal syndrome (Melnick-Fraser syndrome) 29 CHARGE
    [Show full text]